Industrial ectogenesis (hatcheries)
Human beings produced entirely in machinery - eggs fertilized in vitro, embryos bottled on a moving conveyor, and infants decanted after a full engineered gestation, in predetermined numbers and grades.
In shortIndustrial ectogenesis (hatcheries), from Brave New World (Aldous Huxley, 1932), is at technology readiness level 2 of 9 (technology concept formulated) at its weakest link. Held back by Full-term ectogenesis. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $17B–68B.
The Central London Hatchery and Conditioning Centre fertilizes ova in vitro, uses the Bokanovsky Process to split one embryo into up to 96 identical twins, and carries bottled embryos along a 267-day conveyor before decanting.
Closest todayIVF plus neonatal intensive care covers the two ends; artificial-placenta systems have supported preterm lambs for four weeks but no human trial has begun, and human embryo culture stops at about 14 days.
Dependency stack
- Gestation from fertilization to term with no uterus at any stage is the whole premise and no part of the middle trimester has ever been done
- The gap between day-14 embryo culture and artificial-placenta viability covers organogenesis, the hardest and least substitutable phase
- No artificial implantation or placental organ exists to supply hormones and nutrient exchange during that gap
- Scaling implies thousands of parallel units with sterility and uninterrupted power for nine months each
TRL 2- The early half cannot be built without reconstructing implantation and placental exchange
✕3 blockers›
- The placenta's endocrine and nutrient-exchange functions have not been reproduced by any device or culture
- Maternal immune tolerance at the interface is not understood well enough to substitute for
- Human implantation cannot be studied past the 14-day limit, so the critical window is inaccessible
TRL 3 - An engineered placenta is a vascularized tissue that must be grown, not just machined
✕4 blockers›
- Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
- Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
- Cell demand of 10^10-10^11 per organ exceeds current manufacturing
- Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
TRL 4- Without a capillary network, tissue thicker than a few hundred microns dies
✕3 blockers›
- Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
- Engineered endothelium is thrombogenic, so perfused constructs clot
- No method guides anastomosis of a construct's vasculature to host vessels at scale
TRL 3 - Banked-cell organs are not patient-matched, so acceptance must be engineered
✕3 blockers›
- Chronic antibody-mediated rejection proceeds even under current immunosuppression
- Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
- No assay predicts which recipients can be safely weaned off drugs
TRL 5 - One organ needs 10^10-10^11 clinical-grade cells of several types
✕3 blockers›
- Genomic instability and drift accumulate over the expansion needed for 10^11 cells
- Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
- Cost per cell at current media and reagent prices makes a printed organ unaffordable
TRL 6
- Supplies the late-gestation half of the problem
✕4 blockers›
- Miniaturization - the lamb model weighs 1-3 kg while a 23-week human fetus is about 500 g, with shorter umbilical cannulation distances
- Umbilical vessel vasospasm and thrombosis during cannulation and over weeks of support
- Infection control in a continuously exchanged sterile fluid environment
- No agreed proof-of-concept endpoint or animal model that maps onto human neonatal outcomes
TRL 5- Sterile fluid exchange, nutrition and waste handling must run continuously without interruption
✕2 blockers›
- Food production closure
- Microbial and ecological stability over years
TRL 5 - Gas exchange through the umbilical circuit for weeks is the core function
✕3 blockers›
- Blood-surface contact activates coagulation, so runs depend on anticoagulation that causes bleeding in fragile patients
- Oxygenator plasma leakage and fiber fouling limit single-circuit life
- Hemolysis and platelet consumption scale with pump shear and circuit length
TRL 7
- Supplies gas exchange, nutrition and the fetal fluid environment for the late-gestation stretchTRL 5
- The conveyor replaces implantation and the placenta, which must first be understood well enough to substitute forTRL 3
- Industrial output needs gamete supply decoupled from donors
✕3 blockers›
- Human oocyte maturation needs months of follicle growth that culture cannot yet sustain
- Meiotic recombination and chromosome segregation are error-prone outside the ovary, giving aneuploidy
- Imprinting marks are set during germ-cell development and are mis-set in vitro, with no safety assay short of a live birth
TRL 3 - Producing scores of genetically identical individuals on demand is cloning, not twinning
✕3 blockers›
- Incomplete epigenetic reprogramming of the donor nucleus produces placental defects and large-offspring syndrome
- Efficiency is a few percent of transferred embryos, so each live birth consumes many donor eggs and surrogates
- Donor egg supply is the limiting input for any primate-scale program
TRL 5 - Thousands of parallel gestation units imply sterile media, tissue and reagent production at industrial volumeTRL 6
Who could unlock it
- Across several requirements:
- Jacob Hanna 2
- Vitara Biomedical 2
- Nicolas Rivron 2
- Perinatal Life Support (PLS) consortium 2
- Jacob HannaResearcher, Weizmann Institute of ScienceGrew natural mouse embryos ex utero from E5.5 to E11 through organogenesis (Nature, 2021) and generated transgene-free post-gastrulation whole embryo models from naive stem cells (Cell Stem Cell, 2025); holds an ERC grant titled ExUteroEmbryogenesis
- Alejandro Aguilera-CastrejonResearcher, Janelia Research Campus, HHMIBuilt the roller and perfusion ex utero culture platform in the Hanna lab and now works explicitly toward birthing a mouse from an incubator
- Renewal BioStartupIsraeli company co-founded by Hanna in 2022 that licensed the Weizmann ex utero and synthetic-embryo patents (about $9M raised via NFX) to grow early tissue as a cell source
- Vitara BiomedicalStartupWorking the opposite end of the same problem - fluid-filled support from roughly 22 weeks of human gestation onward, the only part of full-term ectogenesis anywhere near clinical use
- Jacob HannaResearcher, Weizmann Institute of ScienceBuilt the ex utero mouse embryo culture platform (Nature, 2021) that the 2026 extension into the fetal period is based on
- Nicolas RivronResearcher, Institute of Molecular Biotechnology, Austrian Academy of SciencesMakes human blastoids that attach to hormonally primed endometrial organoids, and used the assay to screen compounds that block implantation
- Ashley MoffettResearcher, University of CambridgeShowed uterine natural killer cells control extravillous trophoblast differentiation in early pregnancy (Cell Stem Cell, 2024), the core of maternal immune tolerance
- Centre for Trophoblast ResearchAcademic labCambridge centre supplying the trophoblast organoid and placental-interface biology the rest of the field builds on
- Conception BiosciencesStartupReported the first stem-cell-derived human primary oocytes inside entirely iPSC-derived follicle structures, from a blood draw (June 2026)
- Katsuhiko HayashiResearcher, Osaka UniversityProduced healthy fertile mouse pups from iPSC-derived eggs (2016), the only complete mammalian IVG demonstration, and collaborates with Conception
- Mitinori SaitouResearcher, ASHBi, Kyoto UniversityGenerated human oogonia from iPSCs (Science, 2018) and reconstituted human germline epigenetic reprogramming in vitro (Nature, 2024), defining the steps the field has to reproduce
- GametoStartupIts iPSC-derived ovarian support cell product Fertilo produced the first live birth from stem-cell-assisted egg maturation (December 2024) and is in Phase 3 after a $44M Series C in August 2025
- Vitara BiomedicalStartupPhiladelphia company founded in 2019 to commercialise the CHOP EXTEND fluid-filled neonatal support system; filed a $50M Series B offering in October 2024 and remains pre-clearance
- Alan FlakeResearcher, Children's Hospital of PhiladelphiaCo-inventor of EXTEND; his group kept 105-118-day-gestation lambs alive on pumpless umbilical access with protected organ development (2017 onward)
- Marcus DaveyResearcher, Vitara BiomedicalCo-inventor of the EXTEND circuit and leads its preclinical research program
- George MychaliskaResearcher, University of Michigan C.S. Mott Children's HospitalRuns the NIH-funded artificial placenta program in Robert Bartlett's ECMO lab, supporting premature lambs for up to several weeks with lung and brain protection
- Qiang SunResearcher, Institute of Neuroscience, Chinese Academy of SciencesCloned the macaques Zhong Zhong and Hua Hua (2018) and ReTro, the first cloned rhesus to reach adulthood, using trophoblast replacement (2024)
- Institute of Neuroscience, Chinese Academy of SciencesGovernment labThe only group to have produced primate clones; its 2024 result consumed 113 transferred embryos for one surviving animal
- ViaGen Pets and EquineCompanyThe commercial SCNT operation, cloning cats, dogs and horses and the Przewalski's horse Kurt; acquired by Colossal Biosciences in November 2025
- Colossal BiosciencesStartupUses cloning from edited cell lines as its route to live animals and bought ViaGen in 2025 to bring that throughput in-house
Beyond engineering
- The 14-day limit on human embryo culture, codified in law in several jurisdictions, blocks the research the middle of the problem requires
- Legal status of a gestating fetus outside a body, and of the facility that owns it
- Deliberate caste stratification by prenatal treatment is the novel's point and would be illegal discrimination
- Consent and parentage frameworks assume a gestating person